Xultophy Injection is a combination antidiabetic medication containing liraglutide (3.6 mg/mL) and insulin degludec (100 IU), indicated for the treatment of type 2 diabetes mellitus in adults inadequately controlled on oral antidiabetic agents or basal insulin alone. Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and delays gastric emptying, contributing to improved glycemic control and potential weight reduction. Insulin degludec, an ultra-long-acting basal insulin analog, provides a stable and prolonged insulin effect, facilitating consistent glycemic management with reduced risk of hypoglycemia. The fixed-ratio combination allows for once-daily subcutaneous administration, optimizing patient adherence and simplifying treatment regimens. Xultophy is contraindicated in patients with hypersensitivity to its components, medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2. Caution is advised in patients with a history of pancreatitis or severe renal impairment. Adverse effects may include gastrointestinal disturbances, hypoglycemia, injection site reactions, and rare cases of pancreatitis. Dose titration should be individualized based on glycemic response and tolerability. Regular monitoring of blood glucose and clinical status is essential to ensure efficacy and safety. Xultophy Injection represents an effective therapeutic option combining basal insulin and GLP-1 receptor agonist mechanisms to achieve improved glycemic control in type 2 diabetes management.